Promising Data on Cognitive Effects of Safinamide in Early
Parkinson's Disease
• Data presented at Movement Disorder Society’s 11thInternational Congress • Management of cognitive impairment in earlyParkinson’s disease patients is a critical unmet medicalneed Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.(virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX:NWRN) announced today data, which suggest tha...
Phase III Data on Safinamide in Parkinson’s Disease Presented
at American Academy of Neurology 59th Annual Meeting
GENEVA, Switzerland, May 2, 2007 – MerckSerono S.A. (virt-x: SEO) announced today that Phase III data on
safinamide, a new agent in Phase III development for the treatmentof Parkinson’s disease symptoms, were presented by ProfessorFabrizio Stocchi at the American Academy of Neurology 59th AnnualMeeting in Boston, Massachusetts, USA. These d...
Merck Serono Announces Presentation of Phase III Clinical Data on
Safinamide in Parkinson’s Disease at the American Academy of
Neurology 59th Annual Meeting
GENEVA, Switzerland, April 27, 2007 –Merck Serono S.A. (virt-x: SEO) and its partner NewronPharmaceuticals S.p.A. (SWX: NWRN) announced today that ProfessorFabrizio Stocchi, MD, PhD, will present the results of the firstPhase III trial of
safinamide as an adjunctive treatment todopamine agonists (DA) in early Parkinson’s disease (PD)patien...